Arizona State Retirement System Invests $242,000 in Janux Therapeutics, Inc. (NASDAQ:JANX)

Arizona State Retirement System bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the second quarter, according to its most recent filing with the SEC. The firm bought 5,784 shares of the company’s stock, valued at approximately $242,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in Janux Therapeutics by 1.8% during the first quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after acquiring an additional 34,069 shares during the period. Vanguard Group Inc. grew its position in shares of Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Janux Therapeutics in the first quarter valued at about $20,420,000. Altitude Crest Partners Inc. acquired a new stake in shares of Janux Therapeutics in the first quarter valued at about $7,278,000. Finally, StemPoint Capital LP acquired a new stake in shares of Janux Therapeutics in the first quarter valued at about $4,580,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $47.00, for a total transaction of $7,427,457.00. Following the sale, the insider now directly owns 2,959,175 shares of the company’s stock, valued at $139,081,225. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 268,578 shares of company stock valued at $12,071,151. 35.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Stock Down 0.9 %

JANX stock opened at $49.46 on Wednesday. Janux Therapeutics, Inc. has a twelve month low of $5.65 and a twelve month high of $65.60. The company has a market cap of $2.56 billion, a PE ratio of -40.54 and a beta of 3.57. The business’s 50-day simple moving average is $43.14 and its 200 day simple moving average is $44.16.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. The company had revenue of $8.90 million for the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm’s revenue was up 709.1% compared to the same quarter last year. On average, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Analyst Upgrades and Downgrades

JANX has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a research report on Monday. Scotiabank lowered their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Stifel Nicolaus initiated coverage on Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a research report on Monday, August 19th. Finally, Wedbush reissued an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.13.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.